- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Dr. Paul Vogt to Expand Green Chemistry Offering for Pharmaceutical, Petrochemical, Environmental Markets
)--SiGNa Chemistry, Inc., a developer of stabilized reactive metals for safer, more efficient industrial chemistry, has named Paul F. Vogt, Ph.D. as vice president of process development services.
In this newly created position, Dr. Vogt will assume responsibility for developing and operating the central process development laboratory for SiGNa Chemistry located in Monmouth Junction, NJ. An independent operating center for SiGNa Chemistry, the laboratory will focus on developing applications of SiGNa's novel materials for scientific professionals in the Pharmaceutical, Fine Chemical, Petrochemical, Environmental and Consumer industries through custom organic synthesis services and technical consulting. It will also serve as a technical support center for SiGNa's current and future client base and will be the testing grounds and product development arm for SiGNa's future growth.
In addition, Dr. Vogt will serve as a key advisor to SiGNa's president and CEO Michael Lefenfeld. As a member of the company's senior leadership team, he will help drive the company's strategic growth and rapid product development.
"Dr. Vogt's depth of expertise in synthesis scale-up and production will be an invaluable addition to the SiGNa Chemistry team as we enter the company's next stage of commercial growth," said Mr. Lefenfeld. "Building on our core novel reactive materials, SiGNa Chemistry is busy delivering new products and technical services that drive significant improvements in cost, worker safety, and environmental efficiency for both current and future customers."
Dr. Vogt brings over a decade of experience in process research and development, manufacturing, operations and management, including 10 years at the contract research organization, AMRI. He began his career at AMRI in 1997 as a senior research chemist and had taken on positions of increasing responsibility throughout his career. These positions included leading the chemical development efforts at its Mount Prospect Research Center located in the suburbs of Chicago, his promotion in 2005 to director of chemical development, where he oversaw the company's fast-growing chemical development activities, including managing customer projects and project teams involved in process research and scale-up activities, and culminating with his promotion in 2007 to senior director of cGMP manufacturing at AMRI's Rensselaer manufacturing facility. In this role, he was responsible for the manufacturing of all bulk chemicals, pharmaceuticals and intermediates at the company's Rensselaer facility and the small scale cGMP suites located in Albany, NY. His area of oversight included all compounds manufactured at AMRI for human clinical trials and commercial products.
Dr. Vogt holds a bachelor's degree in chemistry from Seton Hall University and a doctorate degree in chemistry from the University of Notre Dame.
About SiGNa Chemistry, Inc.
SiGNa Chemistry, Inc., an advanced materials company, has developed a green nanotechnology-based solution that makes reactive metals far more efficient, safer, and cost effective. Reactive metals are fundamental components used for general synthesis in the pharmaceutical, petrochemical, specialty chemical and environmental remediation industries. It also has the potential to enable portable fuel cells to become practical by safely producing record levels of pure hydrogen gas from a safe, stable dry powder at room temperature. In all of these ventures, the use of reactive metals, such as alkali metals, is currently curtailed or avoided all together due to their high degree of instability which makes them very difficult and expensive to handle. SiGNa’s products have solved the problems of safety and cost efficiency, representing the most substantial scientific breakthrough in reactive metals in over 100 years.
For more information, please click here
Antenna Group (for SiGNa Chemistry)
Rosalind Jackson, 415-977-1923
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016